Small molecule · Antagonist of Substance P/neurokinin 1 receptor (TACR1) · developed by Avyxa Holdings
ApprovedFDA, Jun 2026
1Registered trials
What is Fosaprepitant?
Fosaprepitant is a water-soluble prodrug that is converted to aprepitant after intravenous administration. Aprepitant selectively blocks substance P/neurokinin 1 receptors in the central nervous system, preventing substance P-induced emesis. It is studied in chemotherapy-induced nausea and vomiting.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Navitrux, L-758298
Drug type
Small molecule
Targets
Substance P/neurokinin 1 receptor (TACR1)
Mechanism
Antagonist of Substance P/neurokinin 1 receptor (TACR1)
Pathways
substance P signaling, emesis (central NK-1 receptor blockade)
Nausea and vomiting associated with highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
Delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy (MEC)
From the indications section of the FDA label (version of Jul 29, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.